Researchers from the Hospital Clínic and the Instituto de Salud Global de Barcelona (ISGlobal) have participated in an international multicenter study showing that patients hospitalized with severe COVID-19 and lung involvement treated with remdesivir recovered faster than similar patients who received placebo. .
The study, called the Adaptive COVID-19 Treatment Test (ACTT), has included 1,063 patients and has been promoted by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). In Spain it has been coordinated by the Infectious Diseases Service of the Germans Trias i Pujol Hospital. The results were presented yesterday at the White House by Anthony Fauci, NIAID Director.
Based on a review of the study data by an independent Data Safety Monitoring Board (DSMB), an interim analysis shows that remdesivir was better than placebo from the perspective of the primary objective of the study. rehearsal, time for recovery. This metric is often used in influenza clinical trials. Preliminary results indicate that patients who received remdesivir had a 31% faster recovery time than those who received placebo, with a reduction in 4 days of hospital stay. The median recovery time was 11 days for patients receiving remdesivir compared to 15 days for those receiving placebo. The results also suggest a survival benefit, with a mortality rate of 8% for the group receiving the drug compared to 11.6% for the placebo group.